337 related articles for article (PubMed ID: 32435229)
41. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
[TBL] [Abstract][Full Text] [Related]
42. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
43. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
Kim J; Lee J; Kim C; Choi J; Kim A
Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
[TBL] [Abstract][Full Text] [Related]
44. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
Wang L; Zhang X; Wang ZY
Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
[TBL] [Abstract][Full Text] [Related]
45. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
Chan TW; Pollak M; Huynh H
Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
[TBL] [Abstract][Full Text] [Related]
47. PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling.
Liu HJ; Ooms LM; Srijakotre N; Man J; Vieusseux J; Waters JE; Feng Y; Bailey CG; Rasko JE; Price JT; Mitchell CA
J Biol Chem; 2016 Aug; 291(33):17258-70. PubMed ID: 27358402
[TBL] [Abstract][Full Text] [Related]
48. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
49. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
50. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
51. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
52. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
53. Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.
Watanabe T; Oba T; Tanimoto K; Shibata T; Kamijo S; Ito KI
PLoS One; 2021; 16(6):e0252822. PubMed ID: 34101751
[TBL] [Abstract][Full Text] [Related]
54. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
55. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
Guvakova MA; Surmacz E
Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064
[TBL] [Abstract][Full Text] [Related]
56. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance.
Thomas NB; Hutcheson IR; Campbell L; Gee J; Taylor KM; Nicholson RI; Gumbleton M
Breast Cancer Res Treat; 2010 Feb; 119(3):575-91. PubMed ID: 19288272
[TBL] [Abstract][Full Text] [Related]
57. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
58. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
[TBL] [Abstract][Full Text] [Related]
59. Modulation of BAG-1 expression alters the sensitivity of breast cancer cells to tamoxifen.
Liu H; Lu S; Gu L; Gao Y; Wang T; Zhao J; Rao J; Chen J; Hao X; Tang SC
Cell Physiol Biochem; 2014; 33(2):365-74. PubMed ID: 24557447
[TBL] [Abstract][Full Text] [Related]
60. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line.
Parisot JP; Leeding KS; Hu XF; DeLuise M; Zalcberg JR; Bach LA
Breast Cancer Res Treat; 1999 Jun; 55(3):231-42. PubMed ID: 10517168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
